NCT04799288View on ClinicalTrials.gov

Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
HAM/TSP
Interventions
DRUG

Teriflunomide

Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH